T cell depleted allogeneic PBSC transplantation using CD34+cell selection.

被引：0
|
作者：
Bensinger, W
Cornetta, K
Carabasi, M
Yanovich, S
Hughes, T
Skikne, B
Chabannon, C
Singhal, S
Mills, B
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Indiana Univ, Med Ctr, Indianapolis, IN USA
[3] Univ Alabama, Birmingham, AL USA
[4] Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA
[5] Inst Med & Vet Sci, Adelaide, SA 5000, Australia
[6] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[7] Inst J Paoli I Calmettes, F-13009 Marseille, France
[8] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[9] Nexell Therapeut Inc, Irvine, CA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
850
引用
收藏
页码：199A / 199A
页数：1
相关论文
共 50 条
  • [21] The CD34+cell concentration in peripheral blood predicts CD34+cell yield in the leukapheresis product
    Hollingsworth, KL
    Zimmerman, TM
    Karrison, T
    Oliver, A
    Williams, SF
    CYTOTHERAPY, 1999, 1 (02) : 141 - 146
  • [22] Prediction of CD34+cell yield in haematopoietic cell product in children by peripheral blood CD34+cell count
    Rujkijyanont, P.
    Hipps, J.
    Gan, K.
    Yang, J.
    Wang, C.
    Geiger, T.
    Eldridge, P.
    Leung, W.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S21 - S22
  • [23] CD34+cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies
    Bahçeci, E
    Read, EJ
    Leitman, S
    Childs, R
    Dunbar, C
    Young, NS
    Barrett, AJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (02) : 408 - 414
  • [24] High leukapheresis component Cd34+ cell purity improves CD34+ cell purity following CD34+ cell selection.
    Webb, IJ
    Jiroutek, M
    Cohen, CA
    Schott, DM
    Doss, D
    Freeman, A
    Ritz, J
    Schlossman, RL
    Anderson, KC
    TRANSFUSION, 1998, 38 (10) : 46S - 46S
  • [25] Donor T lymphocyte engraftment is facilitated by higher CD34 cell doses in T cell depleted myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT).
    Battiwalla, M
    Kurlander, R
    Solomon, SR
    Wehrlen, L
    Greene, A
    Barrett, AJ
    BLOOD, 2003, 102 (11) : 709A - 709A
  • [26] The role of CD34+cell number in the peripheral blood during PBSC collection in children with neoplasia
    Stiakaki, E
    Lydaki, E
    Mavroudis, D
    Martimianaki, G
    Katsanoulas, K
    Dimitriou, E
    Perdicogianni, C
    Kantidaki, E
    Kalmanti, M
    BONE MARROW TRANSPLANTATION, 2001, 27 : S307 - S307
  • [27] Transplantation of allogeneic CD34(+) blood cells additionally T-cell depleted with Campath-1H
    Hertenstein, B
    Arseniev, L
    Novotny, J
    Battmer, K
    Stucki, A
    Sudmeier, I
    Pape, I
    Link, H
    Kadar, JG
    Hale, G
    Waldman, H
    Ganser, A
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 293 - 293
  • [28] Nonmyeloablative, T-cell depleted allogeneic peripheral blood stem cell (PBSC) transplantation for patients with chronic granulomatous disease.
    Horwitz, ME
    Barrett, AJ
    Childs, R
    Miller, JA
    Leitman, SF
    Read, EJ
    Carter, CS
    Linton, GF
    Malech, HL
    BLOOD, 1999, 94 (10) : 710A - 710A
  • [29] CD34+cell dose, rather than CFU-GM or CFU-GEMM, is the best predictor of engraftment after T-cell depleted unrelated allogeneic bone marrow transplantation.
    Bolwell, B
    Goormastic, M
    Kalaycio, M
    Andresen, S
    Miller, M
    Mendez, Z
    Serafino, S
    Eles, M
    Demars, D
    Pohlman, B
    BLOOD, 1999, 94 (10) : 145A - 145A
  • [30] Nonmyeloablative stem cell transplantation (NMSCT) with CD8-depleted or CD34-selected PBSC:: A pilot study.
    Baron, FA
    Baudoux, E
    Frère, P
    Fillet, G
    Beguin, Y
    BLOOD, 2001, 98 (11) : 185A - 186A
12345